International Trade

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India.

Patent systems can provide an advantage to society by rewarding the development of new inventions, promoting the advancement of technology and protecting the investor.  Patents often are the most important, and sometimes only, asset of a biotech company. Patents and related rights must be obtained in a timely and predictable manner and the ability to enforce those patents is critical.

Overhauled BIOTradeStatus lets users search for the latest information on hundreds of products.

Bringing biotechs into global health R&D.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

The European Medicines Agency (EMEA), the European equivalent to the Food and Drug Administration (FDA), has implemented an approval scheme that specifically distinguishes between biosimilars (follow-on biologics) and generic drugs.

Tracy Krughoff speaks with Fernando Quesada, executive director of the Biotechnology Center of Excellence Corporation, who is organizing Mexico’s participation in the BIO International Convention.